Alpha-2 Adrenergic Agonists

Localization of $\alpha_2$-Adrenergic Receptors

These receptors are found in two main locations throughout the body:

• Vascular: Located in arterioles of the skin, mucous membranes, coronary vessels, and veins. Their distinctive feature is a predominantly extrasynaptic location.
• Neuronal: Located on postsynaptic membranes and, importantly, on presynaptic membranes (on varicosities of adrenergic and cholinergic nerve terminals).

Additionally, $\alpha_2$-receptors are present on platelets (stimulation causes aggregation), in the gastrointestinal tract (reducing motility and secretion), and in pancreatic $\beta$-cells (decreasing insulin release).

Mechanisms of Action: From Receptor to Effect

The effects of $\alpha_2$-adrenergic agonists depend on the location of the activated receptor.

1. In Vascular Smooth Muscle (Contraction):

Binding to the receptor activates a $G_{i/0}$ protein, which inhibits adenylyl cyclase. This decreases cAMP levels and protein kinase A activity. As a result, myosin light-chain kinase activity increases (facilitating actin-myosin interaction) alongside phospholamban activity. Phospholamban inhibits the sarcoplasmic reticulum $Ca^{2+}$-ATPase, leading to intracellular calcium accumulation and vasoconstriction.

1. On Presynaptic Membranes (Inhibition):

Here, a negative feedback mechanism operates. Activation of the $G_{i/0}$ protein decreases protein kinase A activity, opens potassium channels (causing hyperpolarization), and impairs voltage-gated calcium channels. Less calcium enters the nerve terminal, reducing the exocytosis of vesicles containing neurotransmitters (norepinephrine or acetylcholine).

Classification and Pharmacological Effects

Drugs in this group are divided into topically and centrally acting agents.

Topically Acting Agents (Imidazoline Derivatives): Naphazoline, oxymetazoline, xylometazoline, tetryzoline. Their primary function is to induce pronounced vasoconstriction. They are used in ENT practice for mucosal decongestion (with a longer duration of action than $\alpha_1$-agonists) and in ophthalmology (tetryzoline) for eye irritation.

Centrally Acting Agents: Clonidine, guanfacine, methyldopa, tizanidine. These act on neurons in the nucleus tractus solitarii (NTS). Their stimulation produces central effects:

• Antihypertensive (blood pressure reduction);
• Analgesic;
• Sedative;
• Hypothermic.

Clonidine additionally stimulates imidazoline $I_1$ receptors, enhancing sympathetic nervous system inhibition.

Clinical Application and Side Effects

Topical Formulations: Should not be used more than 3 times daily. Prolonged use (exceeding 5 days) leads to tachyphylaxis (tolerance), and discontinuation can cause "rebound" vasodilation (secondary nasal congestion). Systemic absorption may lead to increased blood pressure.

Central Formulations: Used primarily to treat hypertension (clonidine for hypertensive crises, guanfacine has a longer duration of action). Tizanidine acts as a central muscle relaxant, reducing skeletal muscle tone.

General Side Effects of Central Agents:

• Dry mouth (xerostomia);
• Bradycardia;
• Drowsiness, delayed reaction time;
• Constipation, fluid retention;
• Withdrawal syndrome (upon abrupt cessation).